Shire enters into agreement with Sanquin for CINRYZE

Download PDF Copy

Reviewed

Shire plcAug 25 2015

The company enters into new agreement with Sanquin

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today it has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE® (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE.

"We wanted the freedom to operate and expand in a way that makes strategic sense for our business," said Flemming Ornskov, M.D., CEO, Shire. "When Shire acquired ViroPharma in January 2014, we inherited an arrangement under which Sanquin was the exclusive manufacturer for CINRYZE. We're pleased that Sanquin was open to expanding our partnership and agreeing to support us as we increase production options for this important therapy."

The specific terms of the agreement are confidential, but involve payments to Sanquin on achievement of certain milestones, including a successful technical transfer to a second source manufacturer. Sanquin will continue to serve as a key partner with Shire to increase global supply of CINRYZE.

Source:

Shire plc

Posted in: Business / Finance | Pharmaceutical News

Comments (0)

Download PDF Copy

Suggested Reading

Duke-NUS sharpens focus on population health and technology-enabled research

Daily walking reduces the chances of chronic low back pain

Can ginger help diabetes? Major review says yes, it lowers blood sugar and inflammation effectively

Two-step blood and scan strategy delivers near-perfect accuracy for early Alzheimer's signs

Study finds links between human genetic variation, gut mycobiome, and chronic disease risk

Genetic study shows dual GIPR/GLP1R action curbs binge alcohol use

Beetroot juice lowers blood pressure in older adults by reshaping oral bacteria

CHAPPER healthcare, AscellaHealth’s global pharmaceutical distributor, assumes presidency of EUROPACCESS, enhancing access to innovative medicines

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.